213 related articles for article (PubMed ID: 23887631)
21. Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics.
Calcagno AM; Salcido CD; Gillet JP; Wu CP; Fostel JM; Mumau MD; Gottesman MM; Varticovski L; Ambudkar SV
J Natl Cancer Inst; 2010 Nov; 102(21):1637-52. PubMed ID: 20935265
[TBL] [Abstract][Full Text] [Related]
22. A genome scale RNAi screen identifies GLI1 as a novel gene regulating vorinostat sensitivity.
Falkenberg KJ; Newbold A; Gould CM; Luu J; Trapani JA; Matthews GM; Simpson KJ; Johnstone RW
Cell Death Differ; 2016 Jul; 23(7):1209-18. PubMed ID: 26868908
[TBL] [Abstract][Full Text] [Related]
23. The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects.
Shahbazi J; Liu PY; Atmadibrata B; Bradner JE; Marshall GM; Lock RB; Liu T
Clin Cancer Res; 2016 May; 22(10):2534-44. PubMed ID: 26733615
[TBL] [Abstract][Full Text] [Related]
24. ING5-mediated antineuroblastoma effects of suberoylanilide hydroxamic acid.
Wu JC; Jiang HM; Yang XH; Zheng HC
Cancer Med; 2018 Sep; 7(9):4554-4569. PubMed ID: 30091530
[TBL] [Abstract][Full Text] [Related]
25. Enhancement of tumor initiation and expression of KCNMA1, MORF4L2 and ASPM genes in the adenocarcinoma of lung xenograft after vorinostat treatment.
Kuo WY; Wu CY; Hwu L; Lee JS; Tsai CH; Lin KP; Wang HE; Chou TY; Tsai CM; Gelovani J; Liu RS
Oncotarget; 2015 Apr; 6(11):8663-75. PubMed ID: 25796627
[TBL] [Abstract][Full Text] [Related]
26. Stat3/Oct-4/c-Myc signal circuit for regulating stemness-mediated doxorubicin resistance of triple-negative breast cancer cells and inhibitory effects of WP1066.
Cheng CC; Shi LH; Wang XJ; Wang SX; Wan XQ; Liu SR; Wang YF; Lu Z; Wang LH; Ding Y
Int J Oncol; 2018 Jul; 53(1):339-348. PubMed ID: 29750424
[TBL] [Abstract][Full Text] [Related]
27. The Combination of the M2 Muscarinic Receptor Agonist and Chemotherapy Affects Drug Resistance in Neuroblastoma Cells.
Lucianò AM; Perciballi E; Fiore M; Del Bufalo D; Tata AM
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33182656
[TBL] [Abstract][Full Text] [Related]
28. Sensitivity of osteosarcoma cells to HDAC inhibitor AR-42 mediated apoptosis.
Murahari S; Jalkanen AL; Kulp SK; Chen CS; Modiano JF; London CA; Kisseberth WC
BMC Cancer; 2017 Jan; 17(1):67. PubMed ID: 28109246
[TBL] [Abstract][Full Text] [Related]
29. Thymosin-β4 is a determinant of drug sensitivity for Fenretinide and Vorinostat combination therapy in neuroblastoma.
Cheung BB; Tan O; Koach J; Liu B; Shum MS; Carter DR; Sutton S; Po'uha ST; Chesler L; Haber M; Norris MD; Kavallaris M; Liu T; O'Neill GM; Marshall GM
Mol Oncol; 2015 Aug; 9(7):1484-500. PubMed ID: 25963741
[TBL] [Abstract][Full Text] [Related]
30. Highly synergistic effect of sequential treatment with epigenetic and anticancer drugs to overcome drug resistance in breast cancer cells is mediated via activation of p21 gene expression leading to G2/M cycle arrest.
Vijayaraghavalu S; Dermawan JK; Cheriyath V; Labhasetwar V
Mol Pharm; 2013 Jan; 10(1):337-52. PubMed ID: 23215027
[TBL] [Abstract][Full Text] [Related]
31. The histone deacetylase inhibitor abexinostat induces cancer stem cells differentiation in breast cancer with low Xist expression.
Salvador MA; Wicinski J; Cabaud O; Toiron Y; Finetti P; Josselin E; Lelièvre H; Kraus-Berthier L; Depil S; Bertucci F; Collette Y; Birnbaum D; Charafe-Jauffret E; Ginestier C
Clin Cancer Res; 2013 Dec; 19(23):6520-31. PubMed ID: 24141629
[TBL] [Abstract][Full Text] [Related]
32. Reactivation of silenced α-N-catenin induces retinoic acid sensitivity in neuroblastoma cells.
Clark RA; Newton M; Qiao J; Lee S; Chung DH
Surgery; 2021 Nov; 170(5):1546-1553. PubMed ID: 34092372
[TBL] [Abstract][Full Text] [Related]
33. Dual role of HDAC10 in lysosomal exocytosis and DNA repair promotes neuroblastoma chemoresistance.
Ridinger J; Koeneke E; Kolbinger FR; Koerholz K; Mahboobi S; Hellweg L; Gunkel N; Miller AK; Peterziel H; Schmezer P; Hamacher-Brady A; Witt O; Oehme I
Sci Rep; 2018 Jul; 8(1):10039. PubMed ID: 29968769
[TBL] [Abstract][Full Text] [Related]
34. Cooperation of the HDAC inhibitor vorinostat and radiation in metastatic neuroblastoma: efficacy and underlying mechanisms.
Mueller S; Yang X; Sottero TL; Gragg A; Prasad G; Polley MY; Weiss WA; Matthay KK; Davidoff AM; DuBois SG; Haas-Kogan DA
Cancer Lett; 2011 Jul; 306(2):223-9. PubMed ID: 21497989
[TBL] [Abstract][Full Text] [Related]
35. Acetazolamide potentiates the anti-tumor potential of HDACi, MS-275, in neuroblastoma.
Bayat Mokhtari R; Baluch N; Ka Hon Tsui M; Kumar S; S Homayouni T; Aitken K; Das B; Baruchel S; Yeger H
BMC Cancer; 2017 Feb; 17(1):156. PubMed ID: 28235409
[TBL] [Abstract][Full Text] [Related]
36. Potentiation of apoptosis by histone deacetylase inhibitors and doxorubicin combination: cytoplasmic cathepsin B as a mediator of apoptosis in multiple myeloma.
Cheriyath V; Kuhns MA; Kalaycio ME; Borden EC
Br J Cancer; 2011 Mar; 104(6):957-67. PubMed ID: 21364585
[TBL] [Abstract][Full Text] [Related]
37. Histone deacetylase inhibitors enhance the anticancer activity of nutlin-3 and induce p53 hyperacetylation and downregulation of MDM2 and MDM4 gene expression.
Palani CD; Beck JF; Sonnemann J
Invest New Drugs; 2012 Feb; 30(1):25-36. PubMed ID: 20680659
[TBL] [Abstract][Full Text] [Related]
38. Analysis of the genomic response of human prostate cancer cells to histone deacetylase inhibitors.
Kortenhorst MS; Wissing MD; Rodríguez R; Kachhap SK; Jans JJ; Van der Groep P; Verheul HM; Gupta A; Aiyetan PO; van der Wall E; Carducci MA; Van Diest PJ; Marchionni L
Epigenetics; 2013 Sep; 8(9):907-20. PubMed ID: 23880963
[TBL] [Abstract][Full Text] [Related]
39. Targeting histone deacetylases (HDACs) and Wee1 for treating high-risk neuroblastoma.
Hanmod SS; Wang G; Edwards H; Buck SA; Ge Y; Taub JW; Wang Z
Pediatr Blood Cancer; 2015 Jan; 62(1):52-9. PubMed ID: 25308916
[TBL] [Abstract][Full Text] [Related]
40. Comparing histone deacetylase inhibitor responses in genetically engineered mouse lung cancer models and a window of opportunity trial in patients with lung cancer.
Ma T; Galimberti F; Erkmen CP; Memoli V; Chinyengetere F; Sempere L; Beumer JH; Anyang BN; Nugent W; Johnstone D; Tsongalis GJ; Kurie JM; Li H; Direnzo J; Guo Y; Freemantle SJ; Dragnev KH; Dmitrovsky E
Mol Cancer Ther; 2013 Aug; 12(8):1545-55. PubMed ID: 23686769
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]